Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Kent William Mouw"'
Autor:
Dag Rune Stormoen, Lise Høj Omland, Kent William Mouw, Zoltan Szallasi, Sisse Rye Ostrowski, Susanne Dam Nielsen, Helle Pappot
Publikováno v:
Uro, Vol 4, Iss 1, Pp 1-11 (2024)
Background: This prospective pilot study explored the potential of the innate immune system’s response to cancer-related immuno-stimulants as a predictive biomarker for Immune Checkpoint Inhibitor (ICI) effectiveness, using pembrolizumab-treated me
Externí odkaz:
https://doaj.org/article/5da444d37a8d45088242efdeab200c11
Autor:
David James McConkey, Woonyoung Choi, Susan Halabi, Bin Luo, Hikmat A. Al-Ahmadie, Jonathan E. Rosenberg, Jack Mountain, Ashley Marie Regazzi, Megan Fong, Gopa Iyer, Eliezer Mendel Van Allen, Kent William Mouw, Yujia Wen, Linda McCart, Karla V. Ballman, Himisha Beltran, Michael J. Morris
Publikováno v:
Journal of Clinical Oncology. 40:4562-4562
4562 Background: Our previous work showed that basal tumors were associated with the best clinical outcomes in a Phase 2 clinical trial of neoadjuvant dose-dense MVAC plus B, and in other work we showed that basal tumors were enriched with hypoxia-as
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::caf320f71065342fa8c450463c1039a4
https://doi.org/10.1200/jco.2022.40.16_suppl.4562
https://doi.org/10.1200/jco.2022.40.16_suppl.4562
Autor:
Gopa Iyer, Susan Halabi, Bin Luo, Jonathan E. Rosenberg, Woonyoung Choi, Hikmat A. Al-Ahmadie, Jack Mountain, Ashley Marie Regazzi, Megan Fong, Kent William Mouw, Eliezer Mendel Van Allen, David James McConkey, Yujia Wen, Linda McCart, Karla V. Ballman, Himisha Beltran, Michael J. Morris
Publikováno v:
Journal of Clinical Oncology. 40:4521-4521
4521 Background: Platinum-based chemotherapy is the standard 1st-line therapy for metastatic urothelial cancer (mUC). C90601 was a randomized phase III trial testing gemcitabine and cisplatin (GC) with bevacizumab (B) or placebo (P) in patients (pts)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::53e96ec49863e663cf6b742e88252bf6
https://doi.org/10.1200/jco.2022.40.16_suppl.4521
https://doi.org/10.1200/jco.2022.40.16_suppl.4521
Autor:
Atish Dipankar Choudhury, Wanling Xie, Edmund Folefac, Daniel Lee, Mamta Parikh, David Johnson Einstein, Elizabeth R Kessler, Tina M. Mayer, Rana R. McKay, Amanda Fredericks Pace, Bose Kochupurakkal, Kent William Mouw, Eliezer Mendel Van Allen, Charles Kunos, Alan D. D'Andrea, Mary-Ellen Taplin, Geoffrey Shapiro
Publikováno v:
Journal of Clinical Oncology. 39:5034-5034
5034 Background: Alterations in DNA damage repair (DDR) genes are common in metastatic castration-resistant prostate cancer (mCRPC), and are implicated in responses to carboplatin [carbo], PARP inhibitors and immunotherapeutics. Inhibitors of the ATR
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1d9a06960fecbe7621df6f47b50825f6
https://doi.org/10.1200/jco.2021.39.15_suppl.5034
https://doi.org/10.1200/jco.2021.39.15_suppl.5034